pharma news today glp-1 obesity health drugs october 2025 Outlook for obesity in 2025: more BIG PHARMA NEWS: GLP-1 Revolutionized

These findings suggest that specific patterns of neural connectivity are linked to both metabolic control and cognitive performance in T2DM

Fiber adds bulk and expands in the gut, which can create a painful blockage in a digestive system that has already been slowed down by weight-loss medication

Semaglutide Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), has demonstrated remarkable efficacy in managing weight and improving glycemic control in individuals with Type 2 diabetes mellitus (T2DM) and obesity (23)(39)

When a drug dissolves here, it can enter the bloodstream directly without passing through the gastrointestinal tract or undergoing first-pass metabolism in the liver

J Biol Chem 1948;176:124351